Dyadic receives regulatory approval to initiate phase 1 clinical trial to demonstrate clinical safety and efficacy in humans for dyai-100 covid-19 recombinant protein rbd booster vaccine candidate

Jupiter, fla., oct. 27, 2022 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it has received regulatory approval of a clinical trial application (cta) from the south african health products regulatory authority (sahpra) to initiate a phase 1 clinical trial of the dyai-100 covid-19 receptor binding domain (rbd) booster vaccine.
DYAI Ratings Summary
DYAI Quant Ranking